Gravitas Collective Corp. filed a Schedule 13D with the SEC on October 26, 2026, disclosing beneficial ownership of 25,000,000 shares of Hepion Pharmaceuticals, Inc. common stock following a transaction dated October 6, 2026.

Key Highlights

  • 25,000,000 shares acquired: Gravitas Collective Corp. received 25,000,000 shares of Hepion Pharmaceuticals common stock on October 6, 2026.
  • 19.9% ownership stake: The filing reports the shares represent 19.9% of the issuer's common stock outstanding.
  • Shares outstanding: The percentage is based on 125,073,217 shares of common stock outstanding as of October 6, 2026.
  • Consideration paid: The shares were received in exchange for the membership interests of Gravitas Life Sciences, Inc., which was solely owned by the reporting person.
  • Sole voting and dispositive power: Gravitas Collective Corp. holds sole voting and sole dispositive power over all 25,000,000 shares, with no shared voting or dispositive power.
  • Purpose stated as investment: According to the filing, the common stock was acquired for investment purposes.

Gravitas Collective Corp. Discloses 19.9% Stake in Hepion Pharmaceuticals via Membership Interest Exchange

According to the Schedule 13D filing, Gravitas Collective Corp., a New Jersey corporation with a business address at 155 Pompton Ave., Suite 204, Verona, NJ 07044, became a significant shareholder of Hepion Pharmaceuticals, Inc. on October 6, 2026. The reporting person received 25,000,000 shares of Hepion Pharmaceuticals common stock, par value $0.0001 per share, in exchange for the membership interests of Gravitas Life Sciences, Inc., a company solely owned by the reporting person at the time of the transaction.

The filing identifies the source of funds code as "OO," indicating the consideration was other than personal funds or borrowed funds. The 25,000,000 shares represent 19.9% of the issuer's common stock, calculated using a denominator of 125,073,217 shares outstanding as of October 6, 2026, according to the filing. Gravitas Collective Corp. reports sole voting power and sole dispositive power over all 25,000,000 shares, with zero shared voting or dispositive power reported.

The filing states that the common stock "was acquired for investment purposes" and that the reporting person "may make further acquisitions of the Common Stock from time to time." The filing further states that, beyond this, the reporting person "has no plans or proposals which relate to, or could result in, any of the matters referred to in Item 4 of Schedule 13D." The filing was signed by Chase LoPriore, CEO of Gravitas Collective Corp., on October 26, 2026. No exhibits were filed with the statement.

What Was Disclosed

Gravitas Collective Corp. disclosed a 19.9% beneficial ownership position in Hepion Pharmaceuticals, Inc., consisting of 25,000,000 shares of common stock received in exchange for membership interests of Gravitas Life Sciences, Inc. on October 6, 2026.